Skip to main content
ACG 2023 Annual Meeting Posters Main banner
Back
Rate ePoster

Monday Poster Session

Category: IBD

P2209 - Communication Gap Between Patients and Health Care Professionals on Bowel Urgency With Focus on Crohn's Disease: Results From the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey

Monday, October 23, 2023
10:30 AM – 4:15 PM PT
Location: Exhibit Hall
Has Audio
Stefan Schreiber, MD1, Theresa Hunter Gibble, PhD, MPH2, Marla C. Dubinsky, MD3, David T. Rubin, MD, FACG4, Remo Panaccione, MD5, Toshifumi Hibi, MD, PhD6, Cem Kayhan, MD2, Alison Potts Bleakman, PhD2, Tommaso Panni, PhD7, Angelo D. Favia, PhD2, Christian Atkinson, BSc, MRes8, Simon Travis, 9
1University Hospital Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany; 2Eli Lilly and Company, Indianapolis, IN; 3Mount Sinai Kravis Children’s Hospital, New York, NY; 4University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL; 5University of Calgary, Calgary, AB, Canada; 6Kitasato University, Minato City, Tokyo, Japan; 7Eli Lilly and Company, Bad Homburg, Hessen, Germany; 8Adelphi Real World, Bollington, England, United Kingdom; 9University of Oxford, Oxford, England, United Kingdom

Introduction: Here, we present patient and HCP perspectives on the experiences and impact of Crohn’s disease (CD)-related symptoms from Communicating Needs and Features of IBD Experiences (CONFIDE) survey.

Methods: Online, quantitative, cross-sectional surveys were conducted separately among HCPs and patients with CD from US and EU5 between May and October 2021.

Results: Surveys were completed by 215 US (male [M]=55%, mean age=41 years) and 547 EU5 (M=55%, mean age=38 years) patients. Of these, 58% US and 63% EU5 patients were receiving advanced therapies (biologic/novel oral) and 66% and 63% were receiving steroids at the time of survey completion, respectively. Most patients in the US (61%) and EU5 (62%) reported moderate CD.

The top three symptoms currently (past month) experienced by patients were diarrhoea (US: 55%, EU5: 55%), BU (US: 42%, EU5: 38%), and increased stool frequency (US: 40%, EU5: 37%). Among the patients receiving advanced therapies (US: 58%, EU5: 63%), 46% US and 39% EU5 patients experienced BU and 27% US and 19% EU5 patients reported fistula-related symptoms around the anus/rectum. Among patients experiencing BU, only 40% US and 27% EU5 patients were completely comfortable discussing BU with their HCPs and only 27% US and 23% EU5 patients felt comfortable discussing BU-related accidents. Embarrassment was the most common reason for discomfort associated with discussing BU (US: 73%, EU5: 64%) and BU-related accidents (US: 72%, EU5: 66%) with HCPs.

A total of 200 US (M=78%) and 503 EU5 (M=71%) HCPs completed the surveys. According to HCPs, the top three patient-reported symptoms were diarrhoea (US: 67%, EU5: 66%), blood in stool (US: 44%, EU5: 24%), and increased stool frequency (US: 32%, EU5: 28%). BU was reported among the top three symptoms only by 19% US and 16% EU5 HCPs. Many HCPs (US: 34%, EU5: 40%) reported not proactively discussing BU, with the most common reason being that they “expect the patient to bring this up if this is an issue” (US: 34%, EU5: 42.0%).

Discussion: Similar to the findings in UC patients, BU was the second most reported symptom among patients with CD, but not among the HCP-perceived top three symptoms. A large proportion of patients with moderate-to-severe CD receiving advanced therapies continued to experience BU. These results indicate a communication gap between HCPs and patients with CD, highlighting the underappreciation of the impacts of BU on patients’ daily lives.


Disclosures:
Stefan Schreiber: AbbVie – Personal fees. Amgen – Personal fees. Arena Pharmaceuticals – Personal fees. Biogen – Personal fees. Bristol Myers Squibb – Personal fees. Celgene – Personal fees. Celltrion Healthcare – Personal fees. Dr. Falk Pharma – Personal fees. Eli Lilly – personal fees. Ferring Pharmaceuticals – personal fees. Fresenius Kabi – Personal fees. Galapagos – Personal fees. Gilead – Personal fees. Hikma Pharmaceuticals – Personal fees. I-Mab – Personal fees. Janssen Pharmaceuticals – Personal fees. Morphic – Personal fees. MSD – Personal fees. Mylan – Personal fees. Pfizer – Personal fees. Protagonist – Personal fees. ProventionBio – Personal fees. Sandoz/Hexal – personal fees. Takeda – Personal fees. Theravance Biopharma – Personal fees. UCB – personal fees.
Theresa Hunter Gibble: Eli Lilly and Company – Employee, stockholder.
Marla Dubinsky: AbbVie – Consultant, Grant/Research Support. Arena Pharmaceuticals – Consultant. Astra Zeneca – Consultant. Celgene – Consultant. Genentech Inc. – Consultant. Gilead Sciences – Consultant. Janssen – Consultant, Grant/Research Support. Merck – Consultant. Pfizer – Consultant, Grant/Research Support. Prometheus Biosciences – Consultant, Grant/Research Support. Prometheus Labs – Consultant, Grant/Research Support. Takeda – Consultant, Licensing fees. Thabor – Consultant. Trellus Health – Stock-publicly held company(excluding mutual/index funds). UCB Pharma – Consultant.
David Rubin: AbbVie, Alimentic Inc., Altrubio, Arena Pharmaceuticals, Aslan Pharmaceuticals, Athos Therapeutics – Consultant. Altrubio – Stock Options. American College of Gastroenterology – Advisory Committee/Board Member. Bellatrix Pharmaceuticals, Boehringer Ingelheim, Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos – Consultant. ClostraBio, Connect BioPharma, EcoR1, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ironwood Pharmaceuticals – Consultant. Cornerstones Health, Inc. – Cofounder and CFO. Iterative Scopes, Janssen Pharmaceuticals, Lilly USA, LLC, Materia Prima, Pfizer, Prmometheus Biosciences, Takeda, and Techlab, Inc – Consultant. Takeda – Grant/Research Support.
Remo Panaccione: Abbivax – Consultant. Abbott – Consultant. AbbVie – Consultant. Alimentiv – Consultant. Amgen – Consultant. Arena – Consultant. AstraZeneca – Consultant. Biogen – Consultant. Boehringer Ingelheim – Consultant. Bristol Myers Squibb – Consultant. Celgene – Consultant. Celltrion – Consultant. Cosmos Technology – Consultant. Eisai – Consultant. Elan – Consultant. Eli Lilly – Consultant. Ferring – Consultant. Fresenius Kabi – Consultant. Galapagos – Consultant. Genentech – Consultant. Gilead Sciences – Consultant. GlaxoSmithKline – Consultant. JAMP Bio – Consultant. Janssen – Consultant. Merck – Consultant. Mylan – Consultant. Novartis – Consultant. Oppilan Pharma – Consultant. Organon – Consultant. Pandion Pharma – Consultant. Pendopharm – Consultant. Pfizer Inc – Consultant. Progenity – Consultant. Prometheus – Consultant. Protagonist Therapeutics – Consultant. Roche – Consultant. Sandoz – Consultant. Satisfai Health – Consultant. Shire – Consultant. Sublimity Therapeutics – Consultant. Takeda Pharmaceuticals – Consultant. Theravance Biopharma – Consultant. Trellus – Consultant. UCB – Consultant. Ventyx – Consultant. Viatris – Consultant.
Toshifumi Hibi: AbbVie GK – Consultant, Grant/Research Support, Speakers Bureau. Activaid – Grant/Research Support. Alfresa Pharma – Grant/Research Support. Apo Puls Station – Advisory Committee/Board Member, Consultant. Bristol Myers Squibb – Advisory Committee/Board Member, Consultant, Grant/Research Support. Celltrion – Advisory Committee/Board Member, Consultant. EA Pharma – Advisory Committee/Board Member, Consultant, Study group sponorship. Eli Lilly and Company – Advisory Committee/Board Member, Consultant. Ferring – Grant/Research Support, Speakers Bureau. Gilead Sciences – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. Janssen – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. JIMRO – Study group sponorship, Speakers Bureau. JMDC Inc – Grant/Research Support. Kyorin – Advisory Committee/Board Member, Consultant, Study group sponsorship. Mitsubishi-TanabePharma – Advisory Committee/Board Member, Consultant, Scholarship contributions, Speakers Bureau. Mochida Pharmaceutical – Grant/Research Support, Study group sponorship, Speakers Bureau. Nichi-Iko Pharmaceutical – Advisory Committee/Board Member, Consultant. Nippon Kayaku Co – Grant/Research Support, Scholarship contributions. Otsuka Holdings – Study group sponsorship. Pfizer – Advisory Committee/Board Member, Consultant, Speakers Bureau. Pfizer Japan Inc – Grant/Research Support. Takeda – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. Zeria Pharmaceutical – Advisory Committee/Board Member, Consultant, Scholarship contributions and study group sponsorship.
Cem Kayhan: Eli Lilly and Company – Employee, Stock Options.
Alison Potts Bleakman: Eli Lilly and Company – Employee, Stock Options.
Tommaso Panni: Eli Lilly and Company – Employee, Stock Options.
Angelo Favia: Eli Lilly and Company – Employee, Stock Options.
Christian Atkinson: Adelphi Real World – Employee.
Simon Travis: AbbVie, BUHLMANN Diagnostics, ECCO, Eli Lilly and Company, Ferring Pharmaceuticals – Grant/Research Support. International Organization for the Study of Inflammatory Bowel Disease, Janssen, Merck Sharp & Dohme, Normal Collision Foundation – Grant/Research Support. Pfizer, Procter & Gamble, Schering-Plough, Takeda, UCB Pharma, Vifor Pharma, and Warner Chilcott – Grant/Research Support.


Stefan Schreiber, MD1, Theresa Hunter Gibble, PhD, MPH2, Marla C. Dubinsky, MD3, David T. Rubin, MD, FACG4, Remo Panaccione, MD5, Toshifumi Hibi, MD, PhD6, Cem Kayhan, MD2, Alison Potts Bleakman, PhD2, Tommaso Panni, PhD7, Angelo D. Favia, PhD2, Christian Atkinson, BSc, MRes8, Simon Travis, 9. P2209 - Communication Gap Between Patients and Health Care Professionals on Bowel Urgency With Focus on Crohn's Disease: Results From the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.